Carrier-free siRNA Drugs to Slow Osteoarthritis
Official title: Carrier Free siRNA Conjugates as Disease Modifying Osteoarthritis Drugs
Funded at Vanderbilt University · NIH-11384825 · Data updated 2026-11-12
A new kind of gene-silencing medicine designed to slow bone- and joint-destroying arthritis by targeting the body’s own genes, without using carrier particles.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Vanderbilt University NIH-funded |
| Lab location | 1 site (Nashville, UNITED STATES) |
| Project start | September 10, 2024 |
| Project end | July 31, 2029 |
| Funding year | 2026 |
| Award (this year) | $500,235 |
| NIH project number | 5R01AR083410-03 |
| Project ID | NIH-11384825 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with osteoarthritis or at risk for OA who could benefit from a disease-modifying therapy.
✕Less likely to help
People without OA or with conditions unlikely to respond to joint-targeted siRNA therapies may not benefit.
What this research studies
This project aims to develop carrier-free siRNA therapies that can be used to treat osteoarthritis in the joints, instead of just dampening symptoms. The approach focuses on chemical modifications to protect siRNA molecules and direct them to affected joint tissues. Researchers will design, optimize, and test these conjugates to see if they can slow disease progression in OA. The effort emphasizes manufacturing simplicity and reducing side effects linked to delivery carriers. If successful, it could lead to a new disease-modifying option for people with OA.
Why it matters
Potential benefit: If successful, patients with OA could experience slowed disease progression and improved joint function with fewer side effects compared to current treatments.
How similar studies have gone: Previous siRNA approaches have shown liver-targeted success; this project explores a novel carrier-free approach for joints.
Where this research is happening
-
Vanderbilt University
Nashville, United States Active
Researchers
- Principal investigator: Duvall, Craig Lewis — Vanderbilt University
- Study coordinator: Duvall, Craig Lewis
Related research
Other NIH-funded projects on the same topics.
-
Understanding how knee pain and knee obesity and muscle loss affect knee osteoarthritis
This project looks at how knee swelling, excess knee fat, and muscle loss relate to pain and structural changes in knee osteoarthritis in adults.
-
Identifying OA subtypes and early warning signs before joint damage
This grant asks researchers to find early, invisible clues of osteoarthritis subtypes so we can target treatments before joints are damaged.
-
Digital biomarkers to guide personalized rehab after ACL injury
Aims to use wearable sensors and phone videos to predict early osteoarthritis risk after ACL surgery so rehabilitation can be tailored to each patient.
-
Aberrant mechano-oxygen coupling linked to zinc-rich mineralization in osteoarthritis
Aims to understand how abnormal joint forces affect cartilage and bone, causing zinc-rich mineral deposits and harmful blood vessel growth in osteoarthritis.
-
Notch signaling in TMJ osteoarthritis: uncovering mechanisms and new targets
Researchers are studying how Notch signaling affects TMJ osteoarthritis to identify new ways to protect and repair the jaw joint.
-
Nanoparticles delivering an sPLA2 blocker for knee osteoarthritis
This project uses tiny, drug-filled nanoparticles to deliver an sPLA2-blocking medicine into the knee to reduce inflammation and slow knee osteoarthritis in people with painful knee OA.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.